ReviewClinical & developmental immunology2011
Pathological role of tonsillar B cells in IgA nephropathy.
Review in Clinical & developmental immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Combination therapy with or without warfarin and dipyridamole for severe childhood IgA nephropathy: an RCT.Pediatric nephrology (Berlin, Germany) · 2018Trial
- Binding of IgA1 and surface-expressed collagen-binding protein ofFrontiers in cellular and infection microbiology · 2025Article
- A Case of IgA Nephropathy in a Patient With Sarcoidosis: Confirmation of Glomerular Galactose-Deficient IgA1 Deposition.Case reports in nephrology · 2025Article
- Oral bacteria induce IgA autoantibodies against a mesangial protein in IgA nephropathy model mice.Life science alliance · 2024Article
- Bibliometric analysis of mucosal immunity in IgA nephropathy from 1990 to 2022.Immunity, inflammation and disease · 2024Article
- An 8-month-old boy with infantile nephrotic syndrome caused by semaphorin 3B-associated membranous nephropathy.CEN case reports · 2023Article
- IgA Nephropathy: Current Understanding and Perspectives on Pathogenesis and Targeted Treatment.Diagnostics (Basel, Switzerland) · 2023Review
- Podocytes are likely the therapeutic target of IgA nephropathy with isolated hematuria: Evidence from repeat renal biopsy.Frontiers in pharmacology · 2023Article
- Gut-kidney axis in IgA nephropathy: Role on mesangial cell metabolism and inflammation.Frontiers in cell and developmental biology · 2022Review
- Single-cell RNA-sequencing reveals distinct immune cell subsets and signaling pathways in IgA nephropathy.Cell & bioscience · 2021Article
- IgA glycosylation and immune complex formation in IgAN.Seminars in immunopathology · 2021Review
- Article
- Review
- The Role of Immune Modulation in Pathogenesis of IgA Nephropathy.Frontiers in medicine · 2020Review
- Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies.Theranostics · 2020Review
- Upregulated Expression of Intestinal Antimicrobial Peptide HD5 Associated with Renal Function in IgA Nephropathy.Disease markers · 2020Article
- Glomerular Hematuria: Cause or Consequence of Renal Inflammation?International journal of molecular sciences · 2019Review
- Clinical effects of perazine ferulate tablets combined with eucalyptol limonene pinene enteric soft capsules for treatment of children with IgA nephropathy.Experimental and therapeutic medicine · 2016Article
- A case of synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome complicated by IgA nephropathy with nephrotic syndrome.CEN case reports · 2016Article
- The role of tonsillectomy in IgA nephropathy.Journal of nephrology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although impaired immune regulation along the mucosa-bone marrow axis has been postulated to play an important role, the pathogenesis of IgA nephropathy (IgAN) is unknown; thus, no disease-specific therapy for this disease exists. The therapeutic efficacy of tonsillectomy or tonsillectomy in combination with steroid pulse therapy for IgAN has been discussed. Although randomized control trials for these therapies are ongoing in Japan, the scientific rationale for these therapies remains obscure. It is now widely accepted that abnormally glycosylated IgA1 and its related immune complex (IC) are probably key molecules for the pathogenesis, and are thus considered possible noninvasive biomarkers for this disease. Emerging evidence indicates that B cells in mucosal infections, particularly in tonsillitis, may produce the nephritogenic IgA. In this paper, we briefly summarize characteristics of the nephritogenic IgA/IgA IC, responsible B cells, and underlying mechanisms. This clinical and experimental information may provide important clues for a therapeutic rationale.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.